Polygalasaponin F

CAS No. 882664-74-6

Polygalasaponin F ( —— )

Catalog No. M19225 CAS No. 882664-74-6

Polygalasaponin F has anti-neuroinflammatory activity, can inhibit the release of inflammatory cytokines TNF-α and NO induced by lipopolysaccharides (LPS) and reduce the expression of inducible nitric oxide synthases.

Purity : 98%

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 184 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Polygalasaponin F
  • Note
    Research use only, not for human use.
  • Brief Description
    Polygalasaponin F has anti-neuroinflammatory activity, can inhibit the release of inflammatory cytokines TNF-α and NO induced by lipopolysaccharides (LPS) and reduce the expression of inducible nitric oxide synthases.
  • Description
    Polygalasaponin F has anti-neuroinflammatory activity, can inhibit the release of inflammatory cytokines TNF-α and NO induced by lipopolysaccharides (LPS) and reduce the expression of inducible nitric oxide synthases. Polygalasaponin F can significantly inhibit the cytotoxicity of conditioned medium prepared by LPS-stimulated BV-2 microglia (LPS conditioned media) to neuronal PC12 cells and improve cell viability. Polygalasaponin F can induce long-term potentiation in hippocampal dentate gyrus in anesthetized rats via NMDAR activation mediated by Ca(2+)/calmodulin-dependent kinase II, extracellular signal-regulated kinase and cAMP response element-binding protein signaling pathway. PS-F inhibits the secretions of neuroinflammatory cytokines by the regulation of the NF-kB-signaling pathway.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    NF-κB
  • Research Area
    Others-Field
  • Indication
    ——

Chemical Information

  • CAS Number
    882664-74-6
  • Formula Weight
    1091.3
  • Molecular Formula
    C53H86O23
  • Purity
    98%
  • Solubility
    ——
  • SMILES
    C1C(CC[C@@]2(CC[C@]3([C@@]4(CC[C@H]5[C@]([C@H]([C@H](C[C@@]5([C@H]4CC=C3[C@H]12)C)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)(C)CO)C)C)C(=O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O[C@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)C)O[C@H]1[C@@H]([C@H]([C@@H](CO1)O)O)O)O)O)(C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Zhou W,et al. Quantification of polygalasaponin F in rat plasma using liquid chromatography-tandem mass spectrometry and its pharmacokinetics application. Biomed Chromatogr. 2015 Sep;29(9):1388-92.
molnova catalog
related products
  • K-604

    K-604 is a potent, selective and competitive ACAT-1 inhibitor with IC50 of 0.45 uM for human ACAT-1, displays 229-fold selectivity over ACAT-2.

  • EG1

    EG1, a novel specific inhibitor of Pax2 transcription activation, targets the DNA binding domain and inhibits embryonic kidney development.

  • PIN1 inhibitor API-1

    PIN1 inhibitor API-1 is a specific Pin1 inhibitor (IC50: 72.3 nM). PIN1 inhibitor API-1 retains the active conformation of pXPO5 and restores the ability of pXPO5 to transport pre-miRNAs from the nucleus to cytoplasm, thus up-regulating the anticancer miRNA biogenesis to suppress both in vitro and in vivo hepatocellular carcinoma development.